SCHEDULE: Hellman & Friedman Discloses 19.8% Stake in Medline Inc.

Private equity firm Hellman & Friedman reports a significant 19.8% beneficial ownership in Medline Inc. following its recent initial public offering.

Summary

• Hellman & Friedman (H&F) and its affiliated entities have disclosed an aggregate beneficial ownership of 187,083,713 shares of Class A common stock.
• The total ownership represents 19.8% of the class, based on 845,611,435 shares outstanding plus 100,610,216 shares issuable upon exchange of units.
• The holdings include 74,496,172 shares held by HFCP X Parallel and 100,629,526 shares associated with Mend Investment Holdings I.
• A portion of the ownership consists of 100,610,216 common units of Medline Holdings L.P. that are exchangeable for Class A common stock on a one-for-one basis.
• The disclosure follows the underwriters' full exercise of their option to purchase additional shares as reported in the March 6, 2026, prospectus.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as it confirms the continued commitment of a sophisticated lead investor with deep industry expertise.

Positives

• Significant institutional backing from a premier global private equity firm provides a strong vote of confidence in Medline's long-term value.
• The 19.8% stake indicates a major commitment of capital, aligning the interests of H&F with other Class A shareholders.
• The underwriters' full exercise of their over-allotment option suggests robust market demand for the company's shares during the IPO process.

Negatives

• High concentration of ownership (19.8%) by a single group of affiliated entities may limit the influence of smaller retail and institutional investors.
• The existence of over 100 million exchangeable units represents potential future dilution or significant sell-side pressure if H&F decides to exit its position.

Risks

• Concentrated voting power among H&F entities could influence corporate governance and strategic decisions.
• Future sales of large blocks of shares by the reporting persons could create volatility in the Class A common stock price.
• The exchangeable unit structure adds complexity to the capital stack and calculation of total voting power.

Future Outlook

The filing indicates a passive investment stance typical of Schedule 13G filings, though the significant size of the stake suggests H&F will remain a dominant stakeholder in Medline's post-IPO trajectory. The exchangeable units provide a clear mechanism for H&F to increase its liquid Class A holdings over time.

Management Comments

• The reporting persons may be deemed to beneficially own an aggregate of 187,083,713 shares of Class A common stock.
• Holders of Common Units have the right to exchange their units for shares of Class A Common Stock on a one-for-one basis.
• A three-member board of directors of Investors X Ltd. has voting and investment discretion over the securities.

Industry Context

StockSavvy.ai notes that large private equity stakes in recently public healthcare giants like Medline are common, as these firms often transition from private ownership to public markets while retaining significant influence to ensure strategic execution during the early years of being a public entity.

Comparison to Industry Standards

• The 19.8% stake is comparable to other major PE-backed healthcare IPOs, such as MultiPlan or Avantor, where sponsors retained significant minority positions.
• The use of an 'Up-C' structure with exchangeable units is a standard industry practice for tax efficiency in private equity exits.
• Medline's successful over-allotment exercise places it in the top tier of recent healthcare IPOs regarding market reception.

Corporate Governance

Related Party Transactions

• The exchange agreement dated December 16, 2025, allows H&F entities to exchange partnership units for Medline Inc. Class A common stock.

Stakeholder Impact

• Class A Shareholders: Must account for the 19.8% voting block held by H&F in corporate matters.
• Management: Retains a stable, long-term institutional partner in H&F.
• Market: Potential for increased liquidity if exchangeable units are converted and sold.

Next Steps

• Monitor for any future Schedule 13D filings which would indicate a shift from passive to active investment intent.
• Watch for Form 4 filings indicating any sales or further acquisitions by H&F entities.

Key Dates

Recommendation

The disclosure of a nearly 20% stake by a major private equity firm is a stabilizing factor for a newly public company, but the potential for future large-scale selling warrants a hold rating until the post-IPO lock-up periods and H&F's long-term exit strategy become clearer.

Keywords

Medline Inc., Hellman & Friedman, Schedule 13G, Beneficial Ownership, Private Equity, Class A Common Stock, Institutional Investment, Healthcare Supply Chain